Our findings of mRNA expression levels correlated with survival outcomes will require further experimental validation from PDAC tumor biopsies in future clinical trials monitoring TGFB2 mRNA, IFN-I pathway, and TAM markers for protein, and mRNA measured using quantitative reverse transcription polymerase chain reaction methods. The gene discussed is TGFB2; the disease is neoplasm.